CONTACT INFORMATION

NextGen Sciences

US Office
4401 Varsity Drive, Suite E
Ann Arbor
Michigan 48108
t: +1-888-219-8471 (toll free)
f: +1-888-566-4383 (toll free)

UK Office
Building 56
Alconbury North Airfield
Alconbury, Huntingdon
CAMBS, PE28 4DA
t: +44 (0) 1480 410 850
f: +44 (0) 1480 410 858
biomarkers@nextgensciences.com

Biomarkers

Protein Biomarker discovery, assay development and monitoring solutions from NextGen Sciences.

The protein biomarker services from NextGen Sciences encompass any or all of the following:


Ways to work with NextGen Sciences

NextGen Sciences have a flexible business model and are open to discussion as to how best to fit the customer's needs, for example:


Introduction

Biomarkers, including genomic, proteomic and metabanomic/metabolomic biomarkers, are defined as measurable indicators of a biological state and hold a key position in the new approach to drug development and diagnostics. Biomarkers clearly have enormous potential in the diagnosis of disease and disease progression and are under intense investigation due to their predictive ability and safety indications throughout the drug development process. This includes patient stratification, toxicity, efficacy and patient response to therapy. It is therefore the desire (and most likely will become a requirement) of pharmaceutical companies to develop biomarkers and biomarker assays to aid in the drug development process.

NextGen Sciences are already carrying out projects as outlined here for clients and have the technical expertise and equipment required to conduct these advanced studies. This expertise in the challenging field of protein analysis and proteomics has been developed through the building of a team of highly qualified scientists with previous experience in pharmaceutical, biotech and academic research who are trained to operate our state of the art equipment to generate the desired results. The company has been supplying the highest quality protein science services since it's inception in 2001 and the staff have worked in close cooperation with many major companies and academic institutions around the world.

The FDA is keen that more companies work with them in the earlier stages of biomarker development and provide voluntary data submissions. A pilot process is in place to allow this to happen. It would appear that the FDA would prefer that a single assay was used by a number of pharma/biotech companies for a particular protein than have as many different assays as interested companies.

The initial method of choice for NextGen Sciences will be the mass spectrometry based technique of Multiple Reaction Monitoring (MRM). In addition to sample collection and preparation we have the necessary experience and tools to develop robust quantitative and precise MRM assays to meet the needs of a clinical study. NextGen's close ties to a number of immunological reagent suppliers will speed the development of an assay and allow us to attain the analytical limits that are required. For an example of work carried out using MRM measurements please see Anderson, L. & Hunter, C. L., (2006), Mol Cell Proteomics, 5.4, 573 - 588. NextGen Sciences has presented some of its own data during the 'Mining the Plasma Proteome' stream at the CHI PepTalk Conference, January 7th - 11th 2008. Click here to download a copy of the poster


Assay development
  • Development of the required sample preparation and analytical parameters to assay the protein of interest in the required matrix, for example from plasma, serum, urine, CSF etc.
  • Validation of the assay with regards to limit of detection, limit of quantitation, precision, accuracy and sensitivity.

Monitoring of protein biomarkers from pre-clinical and clinical samples

  • Monitoring of protein biomarkers during all phases from pre-clinical through 'first in man' (Phase 0) to post-market monitoring (Phase IV).
  • Monitoring of proteins present in formalin fixed paraffin embedded (FFPE) tissue samples.

Discovery of protein biomarkers and proteins of interest

  • The identification of clinically relevant proteins (biomarkers) from research and/or clinical samples using a variety of proteomics technologies including, amongst others, label-free MS, iTRAQ, SILAC, spectral counting and 2-dimensional electrophoresis.
  • Identification of proteins present in formalin fixed paraffin embedded (FFPE) tissue samples.

Sample collection

  • In many areas the lack of samples which are fit for purpose is as great an issue as a lack of targeted assays. NextGen Sciences have developed a number of links to academic groups and companies with therapeutic area expertise and access to suitable patient sets.
  • If a suitable sample set is not already available then working with these groups it may be possible to develop a sample collection Standard Operating Procedure (SOP) alongside the assay development and begin sample collection including full patient histories and ethical consent.

Ways to work with NextGen Sciences

NextGen Sciences have a flexible business model and are open to discussion as to how best to fit the customer's needs, for example:

Fee for service

  • Through a straightforward fee for service offering it is possible to engage in a one to one relationship where a customer can fund the assay development for their particular protein biomarkers of interest and can then submit samples for routine analysis and monitoring using these assays. Under this model there are two further options where the customer can retain the exclusive rights to the assays or they can allow NextGen Sciences to offer the assays developed to other customers. These options vary in their pricing structure based upon individual customer requirements

The Consortium model

  • Several companies have expressed an interest in entering into a shared cost, shared risk consortium where a list of protein identities in a particular therapeutic area would be agreed by the consortium members. NextGen Sciences would then develop the assays on this list and make the assays available to each of the consortium members at a discounted price. In this scenario all the rights to the assays would be retained by NextGen Sciences and be made available to the wider market to encourage uptake of these particular assays. A consortium may develop around a particular therapeutic area or could be more general as long as there was interest in a majority of the proteins of interest from the consortium members

Key benefits to working with NextGen Sciences

  • Vast knowledge and experience in the protein sciences arena which is a prerequisite for success in generating these assays and quality data
  • State of the art equipment and facilities
  • Checkpoints built into the project proposals to give regular discussion and decision stages giving the customer full control of the project scale, timescale and budget
  • Scalable solution suited to the needs of our customers
  • Regular open communication on the progress of the project
  • Full data and analysis report at the end of the project

For further information on this area please contact:

Email: biomarkers@nextgensciences.com

Click here to view this information in PDF format

Latest News

NextGen Sciences Announces Commercial Alliance with Paragon Bioservices, Inc.
more >>

New! Biomarkers

NextGen Sciences now offer protein biomarker assay development and monitoring solutions
more >>

Conferences

Join NextGen Sciences at the Biomarkers World Congress on the 19th and 20th May 2008, in Philadelphia
more >>

 

© NextGen Sciences 2008, all rights reserved. ‘NextGen Sciences’ is a trademark of NextGen